Project Grant F31CA290692
Award Date 12/1/25
Completion Date 5/31/27
Dollars Obligated $136K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the University of Colorado-Denver to study the role of the EYA3/PP2A protein complex in regulating the metastatic spread of triple-negative breast cancer (TNBC). The $647,118 award, effective March 1, 2025 through February 28, 2030, supports research aimed at understanding how EYA3 and its interaction with the B55A subunit of PP2A contribute to TNBC metastasis. The project...
- This $161,000 federal Project Grant award, funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at Duke University to investigate "Breast Cancer Brain Metastases: Integrating Immunogenomic and Phenotypic Vulnerabilities to Improve Outcomes." The research aims to develop innovative approaches to understand complex biological systems, create new diagnostic tools, and explore potential therapeutic interventions...
- The U.S. National Cancer Institute (NCI) awarded a $151,040 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant supports research to investigate the role of interferon gamma (IFNγ) in promoting metastasis and immune evasion of triple negative breast cancer (TNBC). Specifically, the project aims to 1) elucidate the role of IFNγ in immune evasion during TNBC dissemination and metastatic...
- This Project Grant award, totaling $102,984, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The award supports research by The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division, to perform spatio-temporal analyses of the entire brain-metastatic arc, from single-cell interaction with the blood-brain-barrier to fully developed brain metastases. The research will...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $719,799 to Health Research, Inc. at Roswell Park in Buffalo, NY to conduct research on the impact of metabolic adaptations on the tumor microenvironment in metastatic triple-negative breast cancer (TNBC). The key objectives are to investigate the bifunctional mechanisms of the PFKFB4 enzyme in regulating metabolic and genetic plasticity in the TNBC tumor microenvironment, and to...
- This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $442,236 to the University of Alabama at Birmingham (UAB) from January 1, 2025 through December 31, 2029. The funding supports research to uncover a novel melanoma metastasis pathway driven by the YTHDF1 RNA-binding protein, and to evaluate therapeutic targeting of the IMPDH1 and TRKB/BDNF pathways that mediate this process. The research utilizes...
- This federal Project Grant award of $223,176, granted by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), will fund research to investigate the role of SMARCAL1 depletion in promoting increased immunogenicity in alternative lengthening of telomeres (ALT)-positive high-grade gliomas. The overarching goal is to examine how therapeutic targeting of SMARCAL1, an annealing helicase, can lead to tumor-specific DNA damage, inflammation, and an enhanced immune...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $700,690.00 to Health Research, Inc. in Buffalo, NY to support research aimed at deciphering the molecular mechanisms of breast cancer bone metastasis. The 5-year project (04/01/2025 - 03/31/2030) seeks to unravel the biological transition from early-stage microscopic bone metastases to established macro-bone metastases, with a focus on understanding the role of the YAP/TAZ...
- This federal Project Grant award, funded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research focused on understanding the relationship between inflammatory signaling in the leptomeninges and the growth of leptomeningeal metastatic tumors. The $730,398 award to the Sloan-Kettering Institute for Cancer Research, located in New York, will leverage mouse models and single-cell RNA sequencing to investigate how cancer cell signals induce...
- This Project Grant award of $2,840,768 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to enhance the therapeutic efficacy and minimize side effects of the chemotherapy drugs cyclophosphamide (CPA) and doxorubicin (DOX) in treating triple-negative breast cancer (TNBC). The key objectives are to improve the metabolic activation of CPA and mitigate the cardiotoxicity of DOX by leveraging dual activation of the human constitutive androstane receptor (HCAR) and...